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SUMMARY 
This retrospective chart review attempts to compare the utility, safety and efficacy of once daily (OD) 
versus divided dose (DD) lithium therapy in the prophylaxis of mood disorders. Sixty-six patients who met 
DSM-II1R criteria for mood disorders were grouped into those on OD Lithium («=_?/) and those on DD 
lithium (n=35). The groups were matched on sociodemographic and clinical variables. The total daily dose 
was similar in the two groups, but the OD group tended to have higher serum lithium levels while the DD 
group tended to have a greater number of affective episodes during the period of follow up. The implicalions 
are discussed. 
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INTRODUCTION 
There are two schools of thought regarding the 
use of lithium in the prophylaxis of mood disor-
ders (Schou et al., 1982) ie. in a single once daily 
(OD) or in divided doses (DD). After the initial 
concerns about renal damage in the absence of 
lithium toxicity (Kassirer, 1983), later reviews 
(Schou, 1988) and biopsy studies (Hetmar et al., 
1991) have shown that lithium does not cause 
significant effects on glomerular filtration rate or 
renal morphology. The OD dosage school avers 
that this dosing improves compliance, and that 
the side effects related to the peak blood levels of 
lithium occur during sleep (Lauritsen et al., 1981). 
The DD schools proposed that a more sustained, 
uniform level would be less damaging to the 
kidney. 
There have been various attempts to com-
pare OD and DD lithium dosing patterns in mood 
disorders. Most results have shown that the side 
effect profile of the OD dosage schedule is com-
parable to DD dosing, and that the benefits were 
better with OD therapy in terms of compliance 
(Plenge & Mellerup, 1986; Muir et al., 1989). 
In India, it is our experience that lithium is 
largely given in divided doses. No studies have 
examined OD lithium therapy. In this study, we, 
therefore, analyzed the benefits and risks of OD 
as compared with DD Lithium therapy in pa-
tients who had been prescribed lithium carbon-
ate for the prophylaxis of mood disorders during 
the same period. We hypothesized that OD 
lithium therapy would be comparable in efficacy 
to DD lithium and would have relatively fewer 
side effects. 
MATERIAL AND METHODS 
Consecutive patients utilizing the inpatient 
and outpatient facilities of one unit of the Depart-
ment of Psychiatry at the National Institute of 
Mental Health and Neurosciences, 
Bangalore,identified during a one year period, 
and who met DSM IIIR criteria (American Psy-
chiatric Association, 1987) for mood disorder 
were selected for the study. Only patients who 
were on lithium for the prophylaxis of mood 
disorders and who were compliant on medica-
tion during the period of follow-up were includ-
ed in the study. 
Sixty-six patients fulfilled the criteria for 
the study. Out of them, 31 were on OD dosing 
and 35 on DD dosing schedules. The case 
charts of these patients were screened systemat-
ically and the data were collected using a 
semistructured proforma. Variables such as 
K» lithium dose, serum lithium levels, use of addi-
tional treatment, adverse drug reactions and the 
occurrence of further episodes were 
operationalized as reported by Suresh et al 
(1995). Serum levels of lithium (measured by 
flame photometry) and side effects recorded by 
the treating clinician were noted. The data re-
garding cessation of treatment, change from one 
dosing pattern to another and occurrence of fur-
ther episodes were also collected as recorded by 
the treating clinician during the period of follow 
up. The data available in the case charts were 
found sufficiently detailed for the purpose of the 
study. 
Blindness could not be ensured as the raters 
had to go through the case notes in detail where 
the dosing pattern is written explicitly. The 
consequent bias was avoided by operationalizing 
certain variables and by having the rating done by 
three of the authors (RM, KPS and KMRP). 
Various definitions for clinical variables that have 
been used in Table 1 were according to DSM-
III-R (American Psychiatric Association, 1987). 
Further details can be obtained from Suresh et al 
(1995). 
The sociodemographic arid clinical param-
eters were assessed as independent variables and 
die treatment, side effects and outcome as de-
pendent variables. Comparisons between the 
two groups were effected using different statisti-
cal methods depending on the variable character-
istics. Qualitative data were compared using 
Yates' continuity-corrected X
2 square test and 
Fisher's (2-tail) exact probability test. The Mann-
Whitney U test was used when the assumptions 
for parametric tests were not satisfied. The 
independent sample t test was used to compare 
means of independent groups Analysis of 
Covariance (ANCOVA) was used to covariate 
out the biasing effect of total dose over serum 
levels between the two groups; the result was 
that serum lithium levels were near significantly 
higher in the OD group as compared with DD 
group (F 1, 47=3.53, p=0.066). The data were 
analyzed using the Statistical Package for Social 
Sciences (SPSS, Ver.4.01). 
RESULTS 
The mean age (SD) of the sample was 
33.2 (12.6) years in the OD group and 26.1 (9.5) 
years in the DD group. The comparison showed 
that the groups did not differ on any of the 
sociodemographicand clinical variables (Table 1). 
TABLE 1: SOCIODEMOGRAPHIC AND 
CLINICAL VARIABLES IN OD & DD LITHIUM GROUPS 
0D(n=31) DD(n=35) SIGNIFICANCE 
Age (years) 
Mean(SD) 33.23(12.63) 28.09(9.52) NS' 
Sex Male 24(77.4%) 24(68.6%) NS" 
Female 7(22.6%) 11(31.4%) 
Diagnosis 
Unipolar 13 14 NS" 
Bipolar 15 18 
Mean previous episode 
Mania 0.86(1.04) 1.38(1.83) NS' 
Depression 0.79(1.03) 0.34(0.7) NS' 
Total 1.64(1.5) 1.72(2.04) NS* 
Family history positive 
Affective 5(17%) 3(19%) NS' 
Non affective 8(28%) 4(9%) NS' 
Previous good 1(3.2%) 2(5.7%) NS"* 
response to lithium 
Elated grandiose 23 26 NS*" 
Psychotic 13(41.9%) 15(44.0%) NS" 
Dysphoria 6(19%) 3(8.6%) NS"' 
ThougntdisorrJer 5(16%) 4(11%) NS"* 
* Mann- Whitney U test; **Continuity correct-
ed Chi-square test; ***Fisher's exact Probabili-
ty (2-tail) test 
105 The proportion of various categories of 
mood disorders in the two groups was compara-
ble. 
The mean daily (SD) lithium dose was 
1003.3 (85.3) mg (range 600 - 1500 mg) in the 
OD group and 1028.6 (221.7) mg (range 600 -
1800mg) in the DD group. The mean serum 
level was slightly higher in the OD group 
(0.72+0.12 mEq/L) as compared with that in the 
DD group (0.65+0.19 mEq/L). The duration of 
follow up was 10.6+6.5 months in the OD group 
and 11,2+5 months in the DD group. The 
differences in the above parameters were not 
significant (Table 2). 
TABLE 2: 
LITHIUM TREATMENT PARAMETERS IN 0D 
& DD LITHIUM GROUPS 
VARIABLE 0D(n=31) DD(n=35) SIGNIFICANCE 
Mean (SD)daily 1003.30(185.3) 1028.60(221.7) NS* 
dose (mg/day) 
Range (mg/day) 600-1500 600-1800 
Mean(SD)semm 10.6(6.5) 11.2(8.5) NS" 
lithium level (mEq/L) 
Meanduration 10.6(6.5) 11.2(8.5) NS* 
of treatment 
(in months) 
*Mann - Whitney U test 
** t test with modified d f to correct for hetero-
geneous variances 
An ANCOVA was performed to ascertain 
whether after covariating out the effect of the 
dose, the serum levels differed between the two 
groups. The frequency of side effects, change in 
dose or therapy due to side effects and need for 
extra treatment (e.g. addition of carbamazepine) 
did not differ significantly between the two groups 
(Table 3). However, 3.27c of OD lithium patients 
had further episodes during the course of follow 
up, while 20Vc in the DD group had relapses. 
This finding just misses statistical significance. 
TABLE 3: 
SIDE EFFECTS AND OUTCOME 
VARIABLE  0D(n=31) DD(n=35) SIGNIFICANCE" 
Side effects seen 
Need to stop lithium 
Need for dose reduction 
Need to change schedule 
Need forextra prophylaxis 
Further affective episodes 
2(6.5%) 
0(0%) 
0(0%) 
0(0%) 
3(9.7%) 
1(3.2%) 
4(11.4%) 
2(5.7%) 
0(0%) 
0(0%) 
6(17%) 
7(20%) 
•Fisher's exact probability (2-tail) test 
NS 
NS 
NS 
NS 
NS 
p=0.058 
Values reported are number and percentage of 
DISCUSSION 
This is the first study in India attempting a 
comparative evaluation of single daily dose lithi-
um therapy versus a divided dose regimen in the 
prophylaxis of mood disorders. Earlier, Surest) 
et al (1995) reported the use of OD lithium in 
acute mania. Lithium being a drug which has to 
be taken for a prolonged period, it is also impor-
tant to explore the utility of a simpler dosage 
schedule in the long term management of mood 
disorders. This study aimed to explore such a 
possibility. 
There are two interesting positive findings 
in this study. First, after correcting for dosage 
influences, the OD lithium schedule was found 
to produce higher 12- hour serum lithium levels 
than the DD lithium schedule. This is believed to 
correlate with the therapeutic efficacy of lithi-
um. Second, the frequency of relapse was 
higher in the DD than in the OD lithium group. 
This may be because of better compliance to OD 
lithium but also raises a theoretical possibility of 
a therapeutic advantage with such a regimen. 
Also, the OD lithium group had higher serum 
lithium levels; although the mean level did not 
differ significantly from that of DD group, it 
must be kept in mind that the difference may be 
yet have been clinically significant. 
The two groups did not differ on other 
outcome measures of efficacy and adverse ef-
fects. The net conclusion is that OD lithium 
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may carry a slight advantage over DD lithium in 
the prophylaxix of mood disorders. 
In several studies, the OD dosing pattern 
has been found to favorably compare with the 
DD pattern (Plenge & Mellerup, 1986; Muir et 
al., 1989). It has been shown that a once-daily 
dose can ensure an adequate 12 hour serum level 
to provide prophylaxix. Of note, the area under 
the curve for serum lithium, plotted against time 
has also been found to be equal in the two groups 
(Plenge & Mellerup, 1986). 
Could dose peaking with OD lithium pre-
dispose to renal adverse effects? In the absence 
of toxicity, renal damage with lithium is unlikely 
(Hetmar et al., 1991). The renal pathology usual-
ly manifests in the early stages as abnormalities in 
renal concentrating mechanisms. The studies 
measuring 24 hour urine output in patients on 
lithium have also proved that OD dosing is more 
favorable in reducing polyuria (O'Donovan, 1993). 
In fact, it is recommended that shifting over to 
OD regimen can be therapeutic in lithium-in-
duced polyuria (Martin, 1993). 
In conclusion, OD and DD lithium regi-
men groups were comparable in 
sociodemographic and clinical variables. The 
side effects and the dosages of lithium did not 
differ significantly in the two groups but showed 
a trend towards higher serum levels on smaller 
total daily doses, with lower incidence of further 
episodes in the OD lithium group. Due impor-
tance needs to be given to schedule of lithium 
administration as this can have important practi-
cal and therapeutic implications in the prophylax-
is of mood disorders. 
This preliminary study suggests the need 
for future research with larger samples, prospec-
tive design, random allocation totfeatment groups, 
structured assessments of efficacy and adverse 
effects and formal evaluation of renal function. 
It is hoped that the findings of the present study 
encourage research on OD lithium therapy. 
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